Penumbra Inc (PEN) : Mariner Wealth Advisors added new position in Penumbra Inc during the most recent quarter end. The investment management firm now holds 137,750 shares of Penumbra Inc which is valued at $10,234,825 , the company said in a statement filed on Aug 12, 2016 with the SEC.Penumbra Inc makes up approximately 0.53% of Mariner Wealth Advisors’s portfolio.
Other Hedge Funds, Including , Primecap Management Coca reduced its stake in PEN by selling 2,200 shares or 2.53% in the most recent quarter. The Hedge Fund company now holds 84,600 shares of PEN which is valued at $6,285,780. Penumbra Inc makes up approx 0.01% of Primecap Management Coca’s portfolio. Globeflex Capital L P added PEN to its portfolio by purchasing 14,640 company shares during the most recent quarter which is valued at $1,087,752. Penumbra Inc makes up approx 0.28% of Globeflex Capital L P’s portfolio.Vanguard Group Inc boosted its stake in PEN in the latest quarter, The investment management firm added 1,470,270 additional shares and now holds a total of 1,529,260 shares of Penumbra Inc which is valued at $113,624,018. Penumbra Inc makes up approx 0.01% of Vanguard Group Inc’s portfolio. State Board Of Administration Of Florida Retirement System added PEN to its portfolio by purchasing 7,055 company shares during the most recent quarter which is valued at $470,639. Swiss National Bank added PEN to its portfolio by purchasing 41,200 company shares during the most recent quarter which is valued at $2,769,052.
On the company’s financial health, Penumbra Inc reported $0.01 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.07. The company had revenue of $65.10 million for the quarter, compared to analysts expectations of $58.18 million. The company’s revenue was up 53.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.11 EPS.
Penumbra Inc. is an interventional therapies company that designs develops manufactures and markets medical devices. The Company has a portfolio of products that addresses medical conditions and clinical needs across two markets which includes neuro and peripheral vascular. Its neuro products include Neurovascular Access Neuron Access System BENCHMARK Intracranial Access System Penumbra System 3D Penumbra Coil 400 Penumbra SMART Coil and LIBERTY stent. The Companys neuro surgical tools include Apollo System. Its peripheral vascular products include Ruby Coil System Penumbra Occlusion Device (POD) and Indigo System. Its products address conditions which include ischemic stroke and hemorrhagic stroke which involve blockage or rupture of blood vessels in the brain and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures which involve the use of medical devices to remove or treat blockages or ruptures of blood vessels.